RxDoctor Payments Data

Penelope Yanni

Psychiatry · Woonsocket, RINPI 1912944414

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 64.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $638 and has fallen 59.3% since, to $260 in 2025.

$1,656in general payments, 2019–2025

Across 78 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$242
  • Otsuka America Pharmaceutical, Inc.$99
  • Lundbeck LLC$45
  • Teva Pharmaceuticals USA, Inc.$37
  • Sage Therapeutics, LLC$27
  • plus $145 from 7 others

What the payments were for

  • Food & beverage$1,62698%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,656 in reported general payments places this provider in the 85th percentile of 209 psychiatry providers in Rhode Island.

See all psychiatry providers in Rhode Island

Medicare billing

Part B allowed, 2024
$37,730
Medicare patients
41
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$58,827
Lurasidone Hcl76$16,339
Aripiprazole94$4,882
Sertraline Hcl164$2,961
Bupropion XlBupropion Hcl97$2,523
Duloxetine Hcl82$2,445
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine52$1,998
Venlafaxine Hcl ErVenlafaxine Hcl68$1,701
Clonazepam196$1,479
Desvenlafaxine Succinate ErDesvenlafaxine Succinate27$1,464
Quetiapine Fumarate72$1,459
Fluoxetine Hcl120$1,387
Mirtazapine80$1,371
Lamotrigine61$1,285
Buspirone Hcl81$1,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$37$58,82713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 209 psychiatry providers in Rhode Island.

Other psychiatry in Woonsocket

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →